Multivalent

BIOLOGICAL5 trials

Sponsors

Pfizer

Conditions

Pneumococcal Infections

Phase 1

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

CompletedNCT02955160

PfizerPneumococcal Infections

Start: 2016-11-03End: 2017-08-01Updated: 2018-09-11

Phase 2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

CompletedNCT03313037

PfizerPneumococcal Infections

Start: 2017-10-10End: 2018-12-10Updated: 2019-12-26

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

CompletedNCT03313050

PfizerPneumococcal Infections

Start: 2017-10-12End: 2019-05-24Updated: 2020-06-04

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

CompletedNCT03512288

PfizerPneumococcal Infections

Start: 2018-04-16End: 2020-02-11Updated: 2021-03-02

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

TerminatedNCT03550313

PfizerPneumococcal Infections

Start: 2018-06-01End: 2020-11-05Updated: 2021-11-30

Related Papers

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial

Human Vaccines & Immunotherapeutics2023-08-013 citations

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

Human Vaccines & Immunotherapeutics2021-03-042 citations

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Human Vaccines & Immunotherapeutics2021-02-0515 citations

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age

Open Forum Infectious Diseases2020-10-012 citations

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Clinical Infectious Diseases2020-07-22156 citations